BioNTech SE
BNT162b2 (2025/2026 formulation)
COVID-19
Countdown
25days
Phase 3 readout · Jul 31, 2026
What's at stake
Phase 3 trial results for BNT162b2 (2025/2026 formulation) in COVID-19 are due Jul 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07222384: Phase 3 trial, sponsor BioNTech SE, drug BNT162b2 (2025/2026 formulation). Primary completion date 2026-07-31 (estimated).”